We are developing two product candidates targeting PCSK9 – VERVE-101 and VERVE-102. These single-course treatments are designed to permanently turn off the PCSK9 gene in the liver to reduce disease-driving LDL-C.
https://www.vervetx.com/our-programs/verve-101-102
https://www.vervetx.com/our-programs/our-pipeline
Ultimately, we plan to further expand to all adults at risk for ASCVD in the general population as a preventative measure.
